Show simple item record

dc.contributor.authorRiudavets, Mariona
dc.contributor.authorMosquera Martínez, Joaquín
dc.contributor.authorGarcía Campelo, María del Rosario 
dc.contributor.authorSerra, Jorgina
dc.contributor.authorAnguera, Georgia
dc.contributor.authorGallardo, Pablo
dc.contributor.authorSullivan, Ivana
dc.contributor.authorBarba, Andrés
dc.contributor.authorDel Carpio, Luís
dc.contributor.authorBarnadas, Agustí
dc.contributor.authorGich, Ignasi
dc.contributor.authorMajem, Margarita
dc.date.accessioned2022-03-16T08:37:20Z
dc.date.available2022-03-16T08:37:20Z
dc.date.issued2020
dc.identifier.issn2234-943X
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/33014837es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16254
dc.description.abstractBackground: Immune-related adverse events (irAEs) have been associated with improved efficacy in advanced non-small cell lung cancer (NSCLC) patients receiving anti-PD-(L)1 blockade agents, while the concurrent use of corticosteroids seems to worsen it. We evaluated outcomes in advanced NSCLC patients treated with anti-PD-(L)1 blockade agents in relation to the presence of irAEs and the reasons for using corticosteroids: whether for palliative cancer-related reasons or for the management of irAEs. Methods: Clinical outcomes in advanced NSCLC patients treated with anti-PD-(L)1 blockade agents were calculated with regard to the presence of irAEs and the use of corticosteroids. A landmark analysis was performed to avoid immortal time bias due to the time-dependent nature of irAEs. Results: Out of a total of 267 patients, the 56.9% of patients who experienced irAEs had significantly improved outcomes. In the landmark analysis, median progression-free survival (PFS) was 12.4 months for patients with irAEs vs. 4.1 months for patients without irAEs (p < 0.001), while median overall survival (OS) was 28.2 vs. 12.5 months, respectively (p < 0.001). Likewise, objective response and disease control rates were significantly higher in patients experiencing irAEs: 48.6 vs. 22.8% and 77.1 vs. 39.6% (p < 0.001), respectively. Median OS was significantly shorter for patients receiving >/=10 mg of prednisone equivalent daily for cancer-related symptoms than for the rest of patients (<10 mg prednisone equivalent daily or for management of irAEs): 6 vs. 15.9 months (p < 0.001). Conclusions: IrAEs were associated with improved efficacy in advanced NSCLC patients when a landmark analysis was applied. Patients receiving corticosteroids had significantly poorer outcomes when they were used for cancer-related symptoms.en
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleImmune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agentsen
dc.typeJournal Articlees
dc.authorsophosRiudavets, Mariona;Mosquera, Joaquin;Garcia-Campelo, Rosario;Serra, Jorgina;Anguera, Georgia;Gallardo, Pablo;Sullivan, Ivana;Barba, Andrés;Del Carpio, Luís;Barnadas, Agustí;Gich, Ignasi;Majem, Margarita
dc.identifier.doi10.3389/fonc.2020.01677
dc.identifier.pmid33014837
dc.identifier.sophos36091
dc.journal.titleFRONTIERS IN ONCOLOGYes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario de A Coruña::Oncoloxía médicaes
dc.relation.publisherversionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505083/pdf/fonc-10-01677.pdfes
dc.rights.accessRightsopenAccess
dc.subject.keywordCHUACes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number10.es


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución 4.0 Internacional